Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions

Figure 2 Bars in this graph indicate SVR12 rates according to gender (male, female), age (< 65 year vs ≥ 65 year), history of interferon-based regimen treatment (+ vs -), level of viremia (< 6. 0 logIU/mL vs ≥ 6.0 logIU/mL), platelet counts (< 10 × 10⁴/mm³vs ≥ 10 × 10⁴/mm³), pretreatment existing L31 substitution [(-): substitution negative, (+): substitution positive], pretreatment existing Y93 substitution [(-): substitution negative, (+): substitution positive], and Y93 and/or L31 [(-): both L31 and Y93 substitution negative, (+): either L31 or Y93 substitution positive, or both L31 and Y93 substitution positive]. M: Male; F: Female; IFN: Interferon.